- LATEST DATA FROM BNC105 & BNO69 PRESENTED AT INTERNATIONAL CONFERENCE -
Key points
o Mechanism for dual effect of BNC105 vascular disruption and cancer cytotoxic action reported, results in tumour “lock-in” of active anti-cancer compound
o The combination of BNC105 and blockbuster cancer drug Avastin® prolonged the collapse of tumour blood vessels o New data BNO69 cancer drug target presented
Adelaide: Bionomics (ASX:BNO) today presented the latest data on its anti-cancer investigational drug BNC105 and the drug target BNO69 at the International Vascular Targeting Therapies in Oncology Conference held in Mandlieu, France.
BNC105
Bionomics’ research scientist Dr Julian Adams presented new data demonstrating the mechanism of action for BNC105 .The data indicated that changes in the pattern within tumour blood vessels of the protein tubulin compared to normal blood vessels may be linked to the selective action of BNC105.
In addition to disrupting tumour blood vessels, BNC105 was found to be directly toxic to cancer cells in vitro, suggesting that the compound targets tumours in two different ways. Further enhancing the anti-tumour activity of BNC105, new data indicated that BNC105 is specifically retained in the tumour mass at high levels for an extended period.
The comprehensive presentation on BNC105 also included data indicating that a combination of BNC105 and blockbuster drug Avastin® induced prolonged vascular shutdown within breast tumours.
The continuing preclinical evaluation of BNC105 strongly supports Bionomics’ plans to undertake clinical trials. Bionomics’ Investigational New Drug (IND) submission with the US Food and Drug Administration is in progress.
BNO69
Dr Tina Lavranos, Bionomics’ Director of Cancer Research, presented evidence that the novel drug target BNO69, is specifically found in the cells that form new blood vessels in solid tumours (the endothelial cells). Targeting BNO69 suppresses the formation of new blood vessels through its effects on the endothelial cell cytoskeleton and disrupting microtubules.
BNO69 is a novel drug target with the potential for providing a new approach to angiogenesis based therapy of cancer and other conditions.
FOR FURTHER INFORMATION PLEASE CONTACT:
Bionomics Limited Dr Deborah Rathjen, CEO & Managing Director +618 8354 6101 / 0418 160 425 drathjen@bionomics.com.au
Media Philippa Harris +612 9237 2800 / 0408 465 800 pharris@bcg.com.au
